CORCEPT THERAPEUTICS INC

Corcept Therapeutics, a pharma leader, trades near $94 on Nasdaq with a $9.78 bn cap—offering a novel cortisol‑blocking therapy for severe metabolic & psychiatric disorders, driving investor confidence and future growth.

Corcept Therapeutics faces a double‑whammy: FDA rejects its steroid‑modulator therapy and a securities lawsuit looms, driving a 16% stock plunge and forcing investors to weigh regulatory risks against future upside.

Corcept Therapeutics shares tumble 8% amid a weak Nasdaq; learn how the company’s cortisol‑modulating therapy and high valuation drive volatility and potential upside.

Corcept Therapeutics Inc. is a leading pharmaceutical company that is making significant strides in developing innovative treatments for severe metabolic and psychiatric disorders through its pioneering approach to cortisol modulation.

Corcept Therapeutics Inc. saw a surge in its share price after a Phase 3 clinical trial showed promising results for its drug relacorilant in treating platinum-resistant ovarian cancer.

Corcept Therapeutics’ shares surged after a Phase 3 clinical trial showed promising results for its treatment relacorilant in combination with nab-paclitaxel for platinum-resistant ovarian cancer.